Sarilumab Biosimilar – Anti-IL-6R mAb – Research Grade

Product nameSarilumab Biosimilar - Anti-IL-6R mAb - Research Grade
SourceDrugBank DB11767
Expression systemMammalian cells
Molecular weight150kDa
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
Aliases /SynonymsSarilumab,Sarilumab,IL-6R,anti-IL-6R
NoteFor research use only. Not suitable for clinical or therapeutic use.
ClonalityMonoclonal Antibody

Description of Sarilumab Biosimilar - Anti-IL-6R mAb - Research Grade

General information on Sarilumab Therapeutic Antibody

The Sarilumab antibody is a fully human IgG1 kappa monoclonal protein targeting the human interleukin 6 receptor (IL-6R). It has been generated using the VelocImmune® platform by Regeneron Pharmaceuticals Inc. which consists of immunizing engineered mice modified to produce fully human antibodies instead of murine immunoglobulins. Sarilumab was granted approval by the Food and Drug Administration (FDA) in 2017 for the treatment of rheumatoid arthritis (RA), an autoimmune condition. RA is a long-term condition affecting hands, feet, and wrists often causing tiredness and weight loss.

Sarilumab and Tocilizumab (a humanized monoclonal antibody) share the same molecular target and mechanism of action. By competitively binding the IL-6R, both antibodies are known to disrupt the pro-inflammatory response caused by the interleukin 6 (IL-9) molecule, a small soluble glycoprotein known to be overexpressed in multiple inflammatory pathologies such as the cytokine release syndrome or “cytokine storm.” Both antibodies have proved their effectiveness as monoclonal antibody therapies in vitro and the clinic.

However, recent studies have shown that Sarilumab’s in vitro binding affinity is 15-22-fold higher than that of Tocilizumab. The improved affinity also translated into a better clinical efficiency suggesting that Sarilumab is capable of effectively blocking the IL-6R with a lower dose and dosage frequency than the ones recurrently necessary in Tocilizumab-based therapies. Consequently, Sarilumab may have an overall lower cost than its humanized counterpart for the treatment of multiple diseases.

The evaluation of Sarilumab as a COVID-19 treatment is currently under regulatory revision. Prior studies with this therapeutic antibody showed a marked improvement in patients in intensive care (over 89% of patients experienced a significant improvement after receiving the antibody intravenously). However, further studies are necessary to access the efficiency and safety of the fully human therapeutic antibody for blocking IL-6R in COVID-19 patients and arrest the onset of the acute respiratory distress syndrome (ARDS) shown to contribute to significant lung damage in the most severe cases of the disease. This product is for research use only.

SDS-PAGE for Sarilumab Biosimilar - Anti-IL-6R mAb

Sarilumab Biosimilar - Anti-IL-6R mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Sarilumab Biosimilar - Anti-IL-6R mAb binds to CD126 Recombinant Protein in indirect ELISA Assay

Immobilized CD126 Recombinant Protein (cat. No.PX-P4104) at 0.5µg/mL (100µL/well) can bind to Sarilumab Biosimilar - Anti-IL-6R mAb (cat. No.PX-TA1028) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450


There are no reviews yet.


Be the first to review “Sarilumab Biosimilar – Anti-IL-6R mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

Human CD126, IL6R, Interleukin-6 receptor subunit alpha recombinant protein

Human CD126, IL6R, Interleukin-6 receptor subunit alpha recombinant protein

PX-P4046 210€
CD126 / IL6R / IL-6RA, C-His, recombinant protein

CD126 / IL6R / IL-6RA, C-His, recombinant protein

PX-P5557 385€
CD126 Recombinant Protein

CD126 Recombinant Protein

PX-P4104 406€
CD126 / IL6R / IL-6RA, N-His, recombinant protein

CD126 / IL6R / IL-6RA, N-His, recombinant protein

PX-P5558 385€
Stable Isotope Labelled Sarilumab Biosimilar – Anti-IL-6R mAb – Research Grade

Stable Isotope Labelled Sarilumab Biosimilar – Anti-IL-6R mAb – Research Grade

PX-TA1028-SIL 15000€
Anti-Sarilumab Polyclonal Antibody
Polyclonal Antibody

Anti-Sarilumab Polyclonal Antibody

PTX18869 650€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.

    Cart (0 Items)

    Your cart is currently empty.

    View Products